2026-09-15T23:41:50Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/97982024-12-18T01:05:31Zcom_10259_6168com_10259_5086com_10259_2604col_10259_6169

Salter, Donald M. Griffin, Meredyth Muir, Morwenna Teo, Katy Culley, Jayne Smith, James R. Gómez Cuadrado, Laura Matchett, Kylie Sims, Andrew H. Hayward, Larry Henderson, Neil C. Brunton, Valerie G. 2024-12-17T12:47:28Z 2024-12-17T12:47:28Z 2019-06 1754-8403 http://hdl.handle.net/10259/9798 10.1242/dmm.038612 1754-8411 Angiosarcomas are a rare group of tumours which have poor prognosis and limited treatment options. The development of new therapies has been hampered by a lack of good preclinical models. Here, we describe the development of an autochthonous mouse model of angiosarcoma driven by loss of p53 in VE-cadherin-expressing endothelial cells. Using Cdh5-Cre to drive recombination in adult endothelial cells, mice developed angiosarcomas with 100% penetrance upon homozygous deletion of Trp53 with a median lifespan of 325 days. In contrast, expression of the R172H mutant p53 resulted in formation of thymic lymphomas with a more rapid onset (median lifespan 151 days). We also used Pdgfrb-Cre-expressing mice, allowing us to target predominantly pericytes, as these have been reported as the cell of origin for a number of soft tissue sarcomas. Pdgfrb-Cre also results in low levels of recombination in venous blood endothelial cells in multiple tissues during development. Upon deletion of Trp53 in Pdgfrb-Cre-expressing mice (Pdgfrb-Cre, Trp53fl/fl mice), 65% developed lymphomas and 21% developed pleomorphic undifferentiated soft tissue sarcomas. None developed angiosarcomas. In contrast, 75% of Pdgfrb-Cre, Trp53R172H/R172H mice developed angiosarcomas, with 60% of these mice also developing lymphomas. The median lifespan of the Pdgfrb-Cre, Trp53R172H/R172H mice was 151 days. Re-implantation of angiosarcoma tumour fragments from Cdh5-Cre, Trp53fl/fl mice provided a more consistent and rapid model of angiosarcoma than the two spontaneous models. The ability to passage tumour fragments through the mouse provides a novel model which is amenable to preclinical studies and will help the development of potential new therapies for angiosarcoma. This work was supported by Cancer Research UK (C157/A15703, C157/A9148 and C6088/A12063), a Wellcome Trust Senior Research Fellowship in Clinical Science (103749) to N.C.H., a Wellcome Trust Clinical Training Fellowship to J.R.S., a Wellcome Trust Institutional Strategic Support Fund award, the Edinburgh and Lothians Health Foundation Margaret Lee Oncology fund, the Charon Fund (registered charity SC022161) and NHS Health Scotland. application/pdf eng The Company of Biologists Disease Models & Mechanisms. 2019, V. 12, n. 7 https://doi.org/10.1242/dmm.038612 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Angiosarcoma TRP53 Genetically engineered mouse model Lymphomas Tumour Oncología Salud Medicina Oncology Health Medicine Development of mouse models of angiosarcoma driven by p53 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Disease Models & Mechanisms 12 7